TITLE

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells

PUB. DATE
January 2009
SOURCE
Radiation Oncology;2009, Vol. 4, p69
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
48166331

 

Related Articles

  • A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation. Lee, Nathan V.; Lira, Maruja E.; Pavlicek, Adam; Jingjing Ye; Buckman, Dana; Bagrodia, Shubha; Srinivasa, Sreesha P.; Yongjun Zhao; Aparicio, Samuel; Rejto, Paul A.; Christensen, James G.; Ching, Keith A. // PLoS ONE;Jun2012, Vol. 7 Issue 6, p1 

    Targeting cancers with amplified or abnormally activated c-Met (hepatocyte growth factor receptor) may have therapeutic benefit based on nonclinical and emerging clinical findings. However, the eventual emergence of drug resistant tumors motivates the pre-emptive identification of potential...

  • c-MET在非小细胞肺癌中的作用机制 及其治疗和检测. 梁红格; 王孟昭 // Chinese Journal of Lung Cancer;12/20/2015, Vol. 18 Issue 12, p745 

    Hepatocyte growth factor/c-MET (HGF/c-MET) signaling pathway can be abnormal activated by many mechanisms such as c-MET mutation, amplification and the overexpression of HGF, and it plays an important role in the development of non-small cell lung cancer (NSCLC), as well as in the tolerance of...

  • An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth. Guessous, Fadila; Zhang, Ying; DiPierro, Charles; Marcinkiewicz, Lukasz; Sarkaria, Jann; Schiff, David; Buchanan, Sean; Abounader, Roger // Anti-Cancer Agents in Medicinal Chemistry;2010, Vol. 10 Issue 1, p28 

    The receptor tyrosine kinase, c-Met and its ligand hepatocyte growth factor (HGF) are important regulators of malignancy in human cancer including brain tumors. c-Met is frequently activated in brain tumors and has emerged as a promising target for molecular therapies. Recently, an orally...

  • 综述. 肺癌细胞中HGF/c-Met信号通路的异常调控及其靶向药物研究进展. 李永文; 刘红雨; 陈军 // Chinese Journal of Lung Cancer;Aug2014, Vol. 17 Issue 8, p625 

    C-MET is a coding product of proto oncogene c-MET, hepatocyte growth factor (HGF) receptor with tyrosine kinase activity. The abnormal expression of c-Met gene is correlated with the tumorigenesis and development of lung cancer. Once the tyrosine kinase is activated by the interaction between...

  • Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer. Tao JIANG; Caicun ZHOU // Chinese Journal of Lung Cancer;4/20/2015, Vol. 18 Issue 4, p240 

    Molecular targeted therapy has become more and more important in the treatment of non-small cell lung cancer (NSCLC). HGF/c-MET plays the pivotal role in the growth, development and tolerance to epidermal growth factor receptor tyrosine kinase inhibitor of NSCLC. Moreover it has become another...

  • HGF-independent potentiation of EGFR action by c-Met. Dulak, A M; Gubish, C T; Stabile, L P; Henry, C; Siegfried, J M // Oncogene;8/18/2011, Vol. 30 Issue 33, p3625 

    The c-Met receptor is a potential therapeutic target for non-small cell lung cancer (NSCLC). Signaling interactions between c-Met and the mutant epidermal growth factor receptor (EGFR) have been studied extensively, but signaling intermediates and biological consequences of lateral signaling to...

  • Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Abounader, Roger; Laterra, John // Neuro-Oncology;Oct2005, Vol. 7 Issue 4, p436 

    The multifunctional growth factor scatter factor/hepatocyte growth factor (SF/HGF) and its receptor tyrosine kinase c-Met have emerged as key determinants of brain tumor growth and angiogenesis. SF/HGF and c-Met are expressed in brain tumors, the expression levels frequently correlating with...

  • Tyrosine kinase receptor indistinguishable from the c-met protein. Giordano, S.; Ponzetto, C.; Di Renzo, M. F.; Cooper, C. S.; Comoglio, P. M. // Nature;5/11/1989, Vol. 339 Issue 6220, p155 

    A letter to the editor is presented about the similarity of tyrosine kinase receptor with the c-met proto-oncogene.

  • cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. Van Der Steen, Nele; Pauwels, Patrick; Gil-Bazo, Ignacio; Castañon, Eduardo; Raez, Luis; Cappuzzo, Federico; Rolfo, Christian // Cancers;2015, Vol. 7 Issue 2, p556 

    In the last decade, the tyrosine kinase receptor cMET, together with its ligand hepatocyte growth factor (HGF), has become a target in non-small cell lung cancer (NSCLC). Signalization via cMET stimulates several oncological processes amongst which are cell motility, invasion and metastasis. It...

  • Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Gujral, T S; Karp, R L; Finski, A; Chan, M; Schwartz, P E; MacBeath, G; Sorger, P // Oncogene;7/18/2013, Vol. 32 Issue 29, p3470 

    Measuring the states of cell signaling pathways in tumor samples promises to advance the understanding of oncogenesis and identify response biomarkers. Here, we describe the use of Reverse Phase Protein Arrays (RPPAs or RPLAs) to profile signaling proteins in 56 breast cancers and matched normal...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics